Now Available at Human Longevity
Early Detection of Pancreatic Cancer Could Save Your Life
Avantect Pancreatic Cancer Test: A simple, DNA-based blood test could help detect pancreatic cancer in its earliest and most treatable stages — especially if you’re at elevated risk.
Testimonial
Pancreatic Cancer is a Silent Killer.
Pancreatic cancer often goes undetected until it has progressed beyond the point of effective treatment. By the time symptoms appear, options are limited. However, when detected early, survival rates increase by more than tenfold.
Now There’s a New Option
The Avantect™ Pancreatic Cancer Test, now available through Human Longevity, is a liquid biopsy that detects tumor-derived genomic signals from a routine blood draw. This is a breakthrough for individuals at high risk — offering the possibility of detection at stage 0 or 1.
Are You High Risk?
You may qualify for testing if you have any of the following:
- IPMN (Intraductal Papillary Mucinous Neoplasm) identified on a prior scan
- A family history of pancreatic cancer
- A recent diagnosis of type 2 diabetes after age 50
- Known genetic predispositions (e.g., BRCA2, PALB2, Lynch syndrome)
Why Human Longevity?
We combine cutting-edge diagnostics, personalized data, and preventative action to help you live longer — and live better.
Our clinical team uses the latest in genomic science to get ahead of disease, not just react to it.
Precision Through Epigenomics
The Avantect test uses a novel DNA biomarker, 5-hydroxymethylcytosine (5hmC), to detect early-stage pancreatic cancer through a simple blood draw. This epigenomic signal reflects active tumor biology, enabling accurate, non-invasive detection with 70% sensitivity and 97% specificity.
Earlier Answers,
Better Outcomes
Avantect outperforms traditional markers like CA19-9, detecting cancer earlier and reducing false positives. In clinical trials and real-world cases, it identified pancreatic cancer in high-risk individuals before imaging or symptoms appeared.
Designed for the Cancer That Hides
Unlike generalized multi-cancer tests, Avantect is purpose-built for pancreatic cancer—one of the most lethal and under-screened cancers. Backed by FDA Breakthrough Designation and ongoing studies, it’s now part of Human Longevity’s advanced detection platform.
GET STARTED
Be One of the First 100 to Access Bleeding-Edge Pancreatic Cancer Screening
The Avantect® test is a groundbreaking blood test that detects early signs of pancreatic cancer by analyzing specific epigenomic markers (5hmC) in cell-free DNA. It offers a non-invasive way to identify cancer at its earliest, most treatable stage.
The test is designed for individuals at higher risk of pancreatic cancer—this includes people over 50 with newly diagnosed type 2 diabetes, those with a family history of pancreatic cancer, or individuals with genetic predispositions (such as BRCA2 mutations).
In clinical studies, the Avantect test demonstrated 68.3% sensitivity and 96.9% specificity for detecting early-stage pancreatic cancer.¹ This makes it one of the most advanced tools available for early detection.
Unlike standard screenings, the Avantect test focuses specifically on pancreatic cancer and uses cutting-edge epigenomic analysis to catch subtle DNA changes. When combined with Human Longevity’s whole genome sequencing and advanced MRI, it forms part of a multimodal approach—providing the most comprehensive early detection strategy available.
Our integrated approach includes:
Whole genome sequencing to identify inherited cancer risks
Advanced whole-body MRI with high-resolution pancreatic imaging
Avantect’s cell-free DNA blood test for early detection of pancreatic cancer
Yes, the Avantect Pancreatic Cancer Test is available to everyone.
Pancreatic Cancer Can No Longer Hide
Human Longevity is proud to launch the Avantect liquid biopsy — a powerful, non-invasive tool for early pancreatic cancer detection. Designed for high-risk individuals, it’s part of our multimodal approach combining…
Whole Genome Sequencing
Revealing inherited cancer risk
High-Resolution MRI
Catching early-stage tumors or structural changes
Avantect Blood Test
Using epigenomic markers (5hmC) with 66.7% sensitivity & 96.9% specificity
This launch aligns with our mission to prevent late-stage cancers — and builds on our $1M Prostate Cancer Pledge to stand behind our science.
